資源描述：
《同步放化療與序貫放化療治療中晚期食管癌的臨床研究》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、·512·JOURNALOFBASICANDCLINICALONCOLOGYVol.24No.6Dec.2011同步放化療與序貫放化療治療中晚期食管癌的臨床研究沈康，肖慶成(南京醫(yī)科大學(xué)第二附屬醫(yī)院泗陽(yáng)分院腫瘤科，江蘇宿遷223700)摘要:目的比較同步放化療與序貫放化療治療中晚期食管癌的近期療效和長(zhǎng)期生存率。方法168例中晚期食管癌患者隨機(jī)分為兩組:同步放化療組91例;序貫放化療組77例。同步放化療組:放療2Gy/次，總量50～56Gy。同步化療2周期，放療結(jié)束后繼2續(xù)化療4周期;序貫放化療組:放療2Gy/次，總量60～64
2、Gy。待放療結(jié)束后化療6周期。兩組化療方案相同:順鉑20mg/m靜脈2滴注d1～5，替加氟400mg/m靜滴d1～5。結(jié)果同步放化療組有效率67．0%，序貫放化療組有效率為59．7%，比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P＞0．05)。同步放化療組1、3年生存率分別為73．6%、49．5%，序貫放化療組1、3年生存率分別為45．5%、24．7%，比較差異均有統(tǒng)計(jì)學(xué)意義(P＜0．05)。兩組毒副反應(yīng)發(fā)生率相似，均可耐受。結(jié)論同步放化療治療中晚期食管癌近期療效肯定，長(zhǎng)期生存有優(yōu)勢(shì)，毒副反應(yīng)可以耐受。關(guān)鍵詞:同步放化療;序貫放化療;中晚期食管癌中
3、圖分類(lèi)號(hào):R730．58;R735．1文獻(xiàn)標(biāo)識(shí)碼:A文章編號(hào):1673－5412(2011)06－0512－03ClinicalResearchofConcurrentChemoradiotherapyandSequentialChemoradiotherapyofAdvancedEsophagealCarcinomaShenKang，XiaoQingcheng(DepartmentofOncology，theSiyangBranchHospitaloftheSecondAffiliatedHospitalofNanjingM
4、edicalUniversity，Suqian223700，China)Abstract:ObjectiveTostudytheshorttermeffectandlongtermsurvivalrateofconcurrentchemoradiotherapyandsequentialchemoradio-therapyofadvancedesophagealcarcinoma．MethodsAllthe168patientswithadvancedesophagealcarcinomawererandomlydivided
5、intotwogroups．The91casesintheconcurrentchemoradiotherapygroup:radiotherapy2Gy/time，thevolumedosewas50-56Gy;2cyclesofchemotherapyweregivenatthesametime，4cyclesofchemotherapyweregivenaftertheradiotherapy．The77casesinthesequentialchemo-radiotherapygroup:radiotherapy2Gy
6、/time，thevolumedosewas60-64Gy;6cyclesofchemotherapyweregivenaftertheradiotherapy．The22chemotherapyregimensofthetwogroupswerethesame:DDP20mg/m，intervenousdropinfusion，d1-5;tegafur400mg/m，intervenousdropinfusion，d1-5．ResultsTheeffectiverateoftheconcurrentchemoradiothe
7、rapygroupwas67．0%，andthatofthesequentialchemora-diotherapygroupwas59．7%(P＞0．05)．The1-，3-yearsurvivalratesoftheconcurrentchemoradiotherapygroupwere73．6%and49．5%，thoseofthesequentialchemoradiotherapygroupwere45．5%and24．7%(P＜0．05)．Thetoxicitiesofthetwogroupswereindis-c
8、riminate，andcouldbetolerated．ConclusionTheshorttermeffectofconcurrentchemoradiotherapyandsequentialchemoradiotherapyaregoodforadvancedesop
